Article thumbnail

Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome

By S Umemura, M Shirane, S Takekoshi, T Kusakabe, J Itoh, N Egashira, Y Tokuda, K Mori and Y R Osamura


The purpose of the present study is to identify genes that contribute to cell proliferation or differentiation of breast cancers independent of signalling through the oestrogen receptor (ER) or human epidermal growth factor receptor 2 (HER2). An oligonucleotide microarray assayed 40 tumour samples from ER(+)/HER2(−), ER(+)/HER2(+), ER(−)/HER2(+), and ER(−)/HER2(−) breast cancer tissues. Quantitative reverse transcriptase PCR detected overexpression of a cell cycle-related transcription factor, E2F-5, in ER-negative breast cancers, and fluorescence in situ hybridisation detected gene amplification of E2F-5 in 5 out of 57 (8.8%) breast cancer samples. No point mutations were found in the DNA-binding or DNA-dimerisation domain of E2F-5. Immunohistochemically, E2F-5-positive cancers correlated with a higher Ki-67 labelling index (59.5%, P=0.001) and higher histological grades (P=0.049). E2F-5-positive cancers were found more frequently in ER(−)/progesterone receptor (PgR)(−)/HER2(−) cancer samples (51.9%, P=0.0049) and in breast cancer samples exhibiting a basal phenotype (56.0%, P=0.0012). Disease-free survival in node-negative patients with E2F-5-positive cancers was shorter than for patients with E2F-5-negative cancers. In conclusion, we identify, for the first time, a population of breast cancer cells that overexpress the cell cycle-related transcription factor, E2F-5. This E2F-5-positive breast cancer subtype was associated with an ER(−)/PgR(−)/HER2(−) status, a basal phenotype, and a worse clinical outcome

Topics: Molecular Diagnostics
Publisher: Nature Publishing Group
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1992). Chem 276: 34958–34965 Dubik D, Shiu RP
  2. (1993). Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F.
  3. (1997). Distinct mechanisms of nuclear accumulation regulate the functional consequence of E2F transcription factors. J Cell Sci 110(Pt 22): 2819–2831 Campanero
  4. (1995). E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle. Proc Natl Acad Sci USA 92: 2403–2407
  5. (2009). E2F-5 in ER/HER2-negative breast cancers S Umemura et al
  6. (1999). Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element.
  7. (1990). Oncol 20: 719–726 Weisz A, Rosales R
  8. (2004). The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.